^
    Back
    Association details:
    Biomarker:KIF5B-RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    World J Surg Oncol
    Title:

    Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report

    Published date:
    12/06/2022
    Excerpt:
    In this report, we describe a patient with PSC harboring a KIF5B-RET gene fusion who was initially diagnosed with stage IVb lung cancer….Based on the next-generation sequencing (NGS) result of RET gene fusion, the patient was treated with pralsetinib. Two months after the treatment, the patient achieved a partial response.
    DOI:
    10.1186/s12957-022-02848-z
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Pharmacol
    Title:

    Novel human-derived RET fusion NSCLC cell lines have heterogeneous responses to RET inhibitors and differential regulation of downstream signaling

    Published date:
    04/01/2021
    Excerpt:
    ...three novel RET-positive(RET+) patient-derived cancer cell lines, CUTO22(KIF5B-RET+), CUTO32(KIF5B-RET+) and CUTO42(EML4-RET+)...CUTO22 and CUTO42 cell lines were sensitive to the selective RET inhibitors RXDX-105 and BLU-667...CUTO22 and CUTO42 cell lines had <50nM IC50 values for RXDX-105 and BLU-667...
    DOI:
    10.1124/molpharm.120.000207